DRUG DEVELOPMENT PIPELINE

Back to the Drug Development Pipeline

OligoG

Phase Two

Phase Two

Therapeutic Approach

Mucociliary Clearance

OligoG is a dry powder drug that has been shown to decrease the thickness of mucus in the lungs and may help individuals with cystic fibrosis clear mucus easier. OligoG may also help improve the effectiveness of some antibiotics. It is administered using a dry powder inhaler and also developed as a liquid for use with a nebulizer.

Status

Two phase 2b trials are ongoing in the United Kingdom, Germany, Sweden, Denmark and Norway.

Sponsor

This program is sponsored by AlgiPharma and partially funded by the Cystic Fibrosis Foundation Therapeutics (CFFT). It is being conducted within CFFT's Therapeutics Development Network.

Contact us about OligoG >